Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Prostate
Descriptor: In vitro studies


Reference Number: 120
Humphrey, P. A. et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147, 386-96 (1995).
PubMed link      E-mail link

Reference Number: 124
Gmyrek, G. A. et al. Normal and malignant prostate epithelial cells differ in their response to hepatocyte growth factor/scatter factor. Am J Pathol 159, 579-90. (2001).
PubMed link      E-mail link

Reference Number: 125
Nishimura, K. et al. Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor. Int J Urol 5, 276-81 (1998).
PubMed link      E-mail link

Reference Number: 221
Davies, G. et al. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int J Cancer 106:348-54 (2003).
PubMed link      E-mail link

Reference Number: 287
Hall CL, Tsan R, Mugnai G, Mazar A, Radinsky R, Pettaway CA. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA). Prostate 59, 167-76 (2004)
PubMed link      E-mail link

Reference Number: 325
MacDougall CA, Vargas M, Soares CR, Holzer RG, Ide AE, Jorcyk CL, Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c. Prostate 64,139-48 (2005)
PubMed link      E-mail link

Reference Number: 363
Forbs D, Thiel S, Stella MC, Sturzebecher A, Schweinitz A, Steinmetzer T, Sturzebecher J, Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol. 27, 1061-70 (2005)
PubMed link      E-mail link

Reference Number: 372
Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene. 25, 2367-78 (2006)
PubMed link      E-mail link

Reference Number: 373
Wells CM, Ahmed T, Masters JR, Jones GE. Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. Cell Motil Cytoskeleton 62, 180-94 (2005)
PubMed link      E-mail link

Reference Number: 378
Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol. 167, 255-66 (2005)
PubMed link      E-mail link

Reference Number: 379
Herter S, Piper DE, Aaron W, Gabriele T, Cutler G, Cao P, Bhatt AS, Choe Y, Craik CS, Walker N, Meininger D, Hoey T, Austin RJ. Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers. Biochem J. 390, 125-36 (2005)
PubMed link      E-mail link

Reference Number: 380
Kirchhofer D, Peek M, Lipari MT, Billeci K, Fan B, Moran P. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 579, 1945-50 (2005)
PubMed link      E-mail link

Reference Number: 381
Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S, Pestell RG, Goldberg ID, Rosen EM. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 24, 1749-66 (2005)
PubMed link      E-mail link

Reference Number: 385
Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 66, 794-802 (2006)
PubMed link      E-mail link

Reference Number: 463
Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mansel RE, Mason MD. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med. 16, 723-8 (2005)
PubMed link      E-mail link

Reference Number: 505
Ye L, Lewis-Russell JM, Davies G, Sanders AJ, Kynaston H, Jiang WG. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. Int J Oncol. 30, 521-9 (2007)
PubMed link      E-mail link

Reference Number: 506
Xu J, Gao M, Fan S, Meng Q, Goldberg ID, Abounader R, Ressom H, Laterra JJ, Rosen EM. Effect of Akt inhibition on scatter factor-regulated gene expression in DU-145 human prostate cancer cells. Oncogene. 26, 2925-38 (2007)
PubMed link      E-mail link

Reference Number: 507
Mukhopadhyay I, Sausville EA, Doroshow JH, Roy KK. Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways. J Biol Chem. 281, 37330-44 (2006)
PubMed link      E-mail link

Reference Number: 508
Maeda A, Nakashiro K, Hara S, Sasaki T, Miwa Y, Tanji N, Yokoyama M, Hamakawa H, Oyasu R. Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. Biochem Biophys Res Commun. 347, 1158-65 (2006)
PubMed link      E-mail link

Reference Number: 509
Tate A, Isotani S, Bradley MJ, Sikes RA, Davis R, Chung LW, Edlund M. Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer. 6, 197 (2006)
PubMed link      E-mail link

Reference Number: 551
Davies G, Ablin RJ, Mason MD, Jiang WG. Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer. J Exp Ther Oncol. 6, 257-64 (2007)
PubMed link      E-mail link

Reference Number: 588
Sanders AJ, Parr C, Mason MD, Jiang WG. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro. Int J Mol Med. 20, 613-9 (2007)
PubMed link      E-mail link

Reference Number: 702
Davies G, Martin TA, Ye L, Lewis-Russell JM, Mason MD, Jiang WG. Phospholipase-C gamma-1 (PLCgamma-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells. Urol Oncol. 26, 386-91 (2008) Epub 2008 Jan 14
PubMed link      E-mail link

Reference Number: 910
Steffan JJ, Williams BC, Welbourne T, Cardelli JA. HGF-induced invasion by prostate tumor cells requires anterograde lysosome trafficking and activity of Na+-H+ exchangers. J Cell Sci. 123(Pt 7), 1151-9 (2010)
PubMed link      E-mail link

Reference Number: 915
Zhang S, Zhau HE, Osunkoya AO, Iqbal S, Yang X, Fan S, Chen Z, Wang R, Marshall FF, Chung LW, Wu D. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer. 9, 9 (2010)
PubMed link      E-mail link

Reference Number: 916
Duhon D, Bigelow RL, Coleman DT, Steffan JJ, Yu C, Langston W, Kevil CG, Cardelli JA. The polyphenol epigallocatechin-3-gallate affects lipid rafts to block activation of the c-Met receptor in prostate cancer cells. Mol Carcinog. 49, 739-49 (2010)
PubMed link      E-mail link

Reference Number: 927
Wang Y, Yue D, Li K, Liu YL, Ren CS, Wang P. The role of TRPC6 in HGF-induced cell proliferation of human prostate cancer DU145 and PC3 cells. Asian J Androl. 12, 841-52 (2010)
PubMed link      E-mail link

Reference Number: 930
Ahmed T, Shea K, Masters JR, Jones GE, Wells CM. A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF. Cell Signal. 20, 1320-8 (2008)
PubMed link      E-mail link

Reference Number: 941
Bright MD, Garner AP, Ridley AJ. PAK1 and PAK2 have different roles in HGF-induced morphological responses. Cell Signal. 21, 1738-47 (2009)
PubMed link      E-mail link

Reference Number: 942
McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2, 673-82 (2009)
PubMed link      E-mail link

Reference Number: 1057
van Leenders GJ, Sookhlall R, Teubel WJ, de Ridder CM, Reneman S, Sacchetti A, Vissers KJ, van Weerden W, Jenster G. Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One. 6, e26753 (2011)
PubMed link      E-mail link

Reference Number: 1352
Varkaris A1, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ, Gallick GE. Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer. 133, 1536-46 (2013)
PubMed link      E-mail link

Reference Number: 1353
Whale AD1, Dart A, Holt M, Jones GE, Wells CM. PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity. Oncogene. 32, 2114-20 (2013)
PubMed link      E-mail link

Reference Number: 1409
Ucar DA1, Magis AT, He DH, Lawrence NJ, Sebti SM, Kurenova E, Zajac-Kaye M, Zhang J, Hochwald SN. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo. Anticancer Agents Med Chem. 13, 595-602 (2013)
PubMed link      E-mail link